QuidelOrtho Corporation filed a Form 8-K on November 3, 2026, disclosing third-quarter 2026 financial results, a cost transformation and enterprise restructuring program, and the appointment of two executives to newly created leadership roles effective November 9, 2026.

Key Highlights

  • Restructuring Plan launched: QuidelOrtho initiated a cost transformation and enterprise restructuring program designed to evolve its operating model around two businesses, Core Diagnostics and Point of Care Diagnostics.
  • Siegrist appointed Head of Point of Care Diagnostics: Jonathan Siegrist, PhD, previously Executive Vice President of Research & Development & Chief Technology Officer, will assume the newly created role effective November 9, 2026.
  • Hanson appointed Head of Core Diagnostics: Bryan Hanson, previously Executive Vice President, Global Portfolio Management and Marketing, will assume the newly created role on the same date.
  • Compensation terms set: Each executive will receive an annual base salary of $650,000, an annual target cash bonus of 100% of base salary, and a cash retention bonus of $650,000 vesting 12 months after the effective date.
  • Equity grants planned: Each executive is to receive a 2027 restricted stock unit award with a grant date value of $2,000,000, vesting in equal annual installments over three years, and a 2028 award also valued at $2,000,000, with the form to be determined later.
  • COO role eliminated: The Board approved the elimination of the Chief Operations Officer position; Phil McLellan's employment as COO will terminate on November 9, 2026, and he will be eligible for severance under his existing agreement.
  • Q3 2026 results announced: A press release reporting financial results for the third quarter ended September 27, 2026, was furnished as Exhibit 99.1 to the filing.

QuidelOrtho Restructures Leadership Around Two Diagnostics Units

According to the filing, QuidelOrtho Corporation (NASDAQ:QDEL) disclosed on November 3, 2026, that its Board of Directors has approved a cost transformation and enterprise restructuring program intended to refocus the company around two distinct business units: Core Diagnostics and Point of Care Diagnostics. The filing states that the restructuring is designed to further improve the company's cost structure and evolve its operating model.

In connection with the Restructuring Plan, the company reported that Jonathan Siegrist, PhD, and Bryan Hanson have been appointed to newly created roles effective November 9, 2026. Dr. Siegrist, formerly the company's Executive Vice President of Research & Development & Chief Technology Officer, will lead Point of Care Diagnostics. Mr. Hanson, formerly Executive Vice President, Global Portfolio Management and Marketing, will lead Core Diagnostics. The filing states that each executive's new employment offer letter provides for an annual base salary of $650,000, an annual target cash bonus opportunity equal to 100% of base salary, and a cash retention bonus of $650,000 payable 12 months after the November 9, 2026 effective date.

The filing also discloses that the Board approved elimination of the Chief Operations Officer role. Phil McLellan, who served in that capacity, will cease employment and his status as an executive officer effective November 9, 2026. The filing states Mr. McLellan will be eligible for severance and other benefits pursuant to his Severance and Change in Control Agreement. Separately, the filing notes that a press release announcing financial results for the third quarter ended September 27, 2026, was furnished as Exhibit 99.1, with an earnings conference call scheduled for 2:00 p.m. Pacific Time on November 3, 2026.

What Was Disclosed

QuidelOrtho's Form 8-K, filed November 3, 2026, covered a new enterprise restructuring plan, two executive appointments with detailed compensation terms, the elimination of the COO role, and the furnishing of third-quarter 2026 earnings materials.